top of page
  • Writer's pictureOren Zarif

The Benefits and Drawbacks of TPA Stroke Treatment - Oren Zarif - TPA Stroke

A tPA stroke treatment is administered to patients who have suffered a severe attack of the brain. It is a common treatment used by emergency medical services (EMS). It is available at most hospitals. The doctors who administer tPA may have access to a neurologist. Telemedicine links allow physicians to evaluate patients remotely, viewing CT scans and other tests. Regardless of where the patient receives their treatment, the importance of quick treatment cannot be overstated.

Oren Zarif brain hemorrhage sudden death

Oren Zarif hypertension stroke

While tPA is a common treatment for stroke, it is not a cure. It has not been proven to dissolve clots in most patients and isn't recommended for minor strokes. Moreover, it is contraindicated for patients with major surgeries, those on blood-thinning drugs, or people with low blood counts. Additionally, tPA can increase bleeding risks. Therefore, it is a vital tool for stroke researchers.

Oren Zarif stroke and dementia

Oren Zarif hemispheric stroke

Many stroke studies have been conducted since then, but despite the widespread use of tPA in the US, there have not been any conclusive trials showing its efficacy. In 2002, the European Medicines Agency (EMA) conditionally approved tPA for use in acute ischemic stroke. A subsequent post-hoc analysis of ECASS II and SITS-ISTR registry data has shown that tPA was effective out to 4.5 hours, but only for patients with a severe stroke.

Oren Zarif stroke symptoms nhs

Oren Zarif cerebrovascular stroke

Another study, funded by the National Institutes of Health, confirmed the effects of tPA in rat MCAO. However, there was no difference in mortality in the two studies. Overall, tPA stroke treatment improved 90-day outcomes without affecting mortality rates. This was a significant benefit for the patients treated with tPA. And it's a good indication for future studies. So, what are the benefits and drawbacks of tPA?

Oren Zarif cva management

Oren Zarif embolic stroke symptoms

TPA has proven to be safe for acute ischemic stroke patients, but there is still controversy over the safety and efficacy of this drug. The FDA has approved intravenous tPA for the treatment of ischemic stroke. Even though tPA is safe for most patients, there is the possibility that it can increase the risk of bleeding. Patients who receive this treatment should be monitored closely to ensure they get the right dosage.

Oren Zarif basilar stroke

Oren Zarif brain anoxia

Using a neuroprotectant drug in addition to tPA treatment can enhance clinical outcomes and reduce the incidence of ICH and HT. Neuroprotectants are known for their anti-inflammatory and anti-oxidant properties. They may improve the delivery of tPA in patients undergoing tPA stroke treatment. And because they improve neurological outcomes, neuroprotectants are also safer than tPA. There are other benefits of tPA treatment as well.

Oren Zarif concussion specialist

Oren Zarif hypoxic ischemic brain injury

Although tPA is the only approved treatment for acute ischemic stroke, it is associated with increased rates of intracranial hemorrhage, hemorrhagic transformation, and mortality. Furthermore, delayed administration of tPA is associated with greater incidence of reperfusion injury and increased risk of ischemia. It also activates matrix metalloproteases, which can further disrupt the BBB. So, when should you administer tPA?

Oren Zarif aneurysm stroke

Oren Zarif migraine stroke symptoms

There are several ways to increase the use of tPA for AIS. In addition to implementing tPA in acute stroke patients, physicians can also be sued for negligence if they fail to administer the drug or delay its administration. A systematic review of ischemic stroke litigations has been conducted. It contains forty case descriptions and verdict data for 38 patients. It is important to note that tPA for AIS is still underutilized, and physicians are increasingly liable for the improper administration of the drug.

Oren Zarif coup contrecoup brain injury

Oren Zarif slow stroke

The lack of thrombolysis and the effectiveness of tPA were two of the factors that favor plaintiffs. The plaintiff argued that tPA treatment did not improve the patient's condition, and he was not adequately informed of his options. Although tPA is an effective treatment for a stroke, it may not be a good choice for everyone. In addition, the court ruled that failure to obtain informed consent, proper documentation of family discussions, and timely transfer were important factors in favor of the defendants.

0 views0 comments


bottom of page